We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Proteome Sciences Plc | PRM | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| -0.07 | -2.62% | 2.60 | 16:35:15 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 2.60 | 2.67 |
| Industry Sector |
|---|
| PHARMACEUTICALS & BIOTECHNOLOGY |
| Top Posts |
|---|
Posted at 27/11/2024 07:21 by wrighty41 Very surprised at the lack of notifiable commercial progress by PRM this year, as represented by the share price.Earlier in the year PRM said that 2024 would see a ‘return ro growth’. If this isn’t delivered then it will be a huge disappointment. W41 |
Posted at 12/11/2024 13:06 by small crow Harking back to the title of the thread, for any that remember the significance, here is an excellent video explaining up-to-date understanding of tau-protein and prion assemblies in the development of AD. (Dom, we fully understand if you just pretend to watch it). Well ahead of their time as usual, it seems PRM were correct in focussing on the prion-tau relationship and similarities in their AD research. Whether any of their understanding can ever be monetised is, as they say, another matter, As they also say, we shall see. |
Posted at 07/11/2024 14:21 by elpirata PRM IP infringement alert!Arlington Chetwynd Talbott7 Nov '24 - 14:05 - 29347 of 29347 0 0 0 Can everyone just calm down?.....KEFI is all about finding something else to do while you wait. |
Posted at 06/11/2024 18:03 by canaletto Good to see almost every worldwide stock has had a positive bounce...apart from Prm of course. Even Trump looks like a saint compared to Pearce. |
Posted at 31/10/2024 11:21 by wrighty41 The commercial progress PRM have made this year has been very disappointing & has resulted in yet another CEO ‘walking away’.I was hoping for a 6p share price by y/e 2024 but that now seems to have been wildly optimistic! W41 |
Posted at 17/10/2024 12:12 by barry evans wasjobber - 05 Jul 2011 - 10:01:20 - 1612 of 93165 Proteome Sciences leading Alzheimer's technology. - PRMFrom the recent annual report. PRM are now in the last stage of their development, commercialization of their hugely valuable IP portfolio and products. Very interesting times lay ahead me thinks! |
Posted at 14/10/2024 10:16 by goatherd Don't forget that PRM not only has something to sell, which is selling well, and of which a new version is expected to sell even better.And potentially large amounts of royalties once someone, somewhere, infringes their very extensive patents; or gets a strike test onto the market. |
Posted at 11/10/2024 18:27 by alchemy I have a Google alert for TMT a lagging indicator of time spent here. The content nevet ever relates to PRM |
Posted at 22/8/2024 11:12 by colinhy Goetherd re your post #93009Many companies have already produced highly accurate tests which Proteome Sciences has already acknowledged do not fall within the scope their IP this is because the methodology those companies use require only one or two of the markers identified in Proteome Sciences IP. It seems to me that there will be little scope for PRM to commercialise its Alzheimer's IP which has multiple marker methodology because a growing number of simpler one or two marker tests are already coming to the market. It difficult to see how Proteome Sciences IP is critical to the development of novel diagnostic tests for Alzheimer’s disease as stated the Proteome Sciences Final Fesults for 2023. as many companies have already produced Alzheimer’s tests without falling within the scope of PRM IP. |
Posted at 22/7/2024 11:27 by sandcrab2 The excellent Fgnoms covered this 13 years ago“fgnoms30 Apr '11 - 10:28 - 14 of 26 0 0 0 Well here we are at the end of April and still no commercial money-making contracts have been signed. CJP at the time of the money raising reiterated break even for 2010, which would have required a few such contracts to have been signed in say late Q3 2010. So seven months on and NO such deals have been signed. I guess the important question is why? Of course we have suffered the same sorry story for the last 4 years on stroke. Yes 4 years ago contracts were imminent and apparently still are but we haven't been told why they haven't been signed. The obvious explanation is that PRM stroke biomarkers together with other panel constituents don't work well enough and therefore a stroke panel cannot be commercialised. Remember all those companies testing the PRM stroke biomarkers - and absolutely nothing has resulted. I think it would now be reasonable to assume that stroke is dead. So what about AD. Yes we are now at the same stage as stroke was 4 years ago. Tests are being carried out - but this time by PRM itself. This indicates to me that none of the big boys have any faith whatsoever in PRM's AD biomarkers - especially since the Dutch revelation that Clusterin isn't a predictive biomarker. So why does PRM continue to lead us on that a commercial deal is just around the corner. I find this bizarre. As PRM is now carrying out its own tests on its own panel nobody is going to sign anything until the results are known - which will probably be in H1 2012. And even then it really isn't feasible that a final saleable AD working panel will only contain PRM biomarkers, is it? So in my view we are years away from a working AD panel. So where does all this optimism come from - cloud cuckoo land imho. So before my next post we will know the 2010 results - a complete disaster no doubt. A loss of nearly £5m compared with target breakeven. 2011 is also looking like another £5m loss as I don't believe any commercial contracts will be signed. 2012 may not be much better either and thats when the cash runs out. So what will the share price be when all this is revealed next month? A very far cry from anything the rampers are saying thats for sure.” |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
